Jackson Heart Clinic | Jackson, MS

Research site

(Unclaimed)

Location

970 Lakeland Dr Suite 61, Jackson, Mississippi, United States of America

Site insights

Top conditions

Top treatments

sodium

aspirin

Edoxaban

Milvexian

Inclisiran

Ziltivekimab

prasugrel

valsartan

cholesterol

Vitamin K

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 43 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling

Primary Prevention of Atherosclerotic Cardiovascular Disease

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Drug: Placebo in 1.5ml

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling

Acute Coronary Syndrome

Drug: Milvexian

Other: Placebo

Amplatzer Amulet LAAO vs. NOAC (CATALYST)

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valv...

Enrolling

Atrial Fibrillation

Stroke

Drug: Non-Vitamin K Oral Antagonists

Device: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Not yet enrolling

Acute Myocardial Infarction (AMI)

Cardiovascular Risk

Drug: Ziltivekimab

Drug: Placebo

Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study

Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Rest...

Enrolling

Dilated Cardiomyopathy

Heart Failure With Reduced Ejection Fraction (HFrEF)

Device: AccuCinch Ventricular Restoration System

Drug: Guideline-Directed Medical Therapy

DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation (Diamond-AFII)

The purpose of the Diamond-AF II study is to establish the safety and effectiveness of the DiamondTemp Ablation System for the treatment of drug refr...

Active, not recruiting

Atrial Fibrillation

Persistent Atrial Fibrillation

Device: Radiofrequency Ablation

Encore PFO Closure Device - The PerFOrm Trial

The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when c...

Enrolling

Cryptogenic Stroke

Patent Foramen Ovale

Device: FDA-approved PFO closure device

Device: Encore PFO closure device

Esprit BTK Post-Approval Study (EspritBTKPAS)

The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK...

Begins enrollment this month

Chronic Limb-Threatening Ischemia

Device: Esprit BTK System

LIFE-BTK Randomized Controlled Trial

The objective of this prospective, single-blinded, randomized controlled clinical investigation is to evaluate the safety and efficacy of the everoli...

Active, not recruiting

Critical Limb Ischemia (CLI)

Device: Percutaneous Transluminal Angioplasty (PTA) Device

Device: Esprit BTK Device

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome (V-INCEPTION)

The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisira...

Active, not recruiting

Acute Coronary Syndrome

Drug: Inclisiran

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg